<DOC>
	<DOCNO>NCT00464958</DOCNO>
	<brief_summary>Open label , one year extension study evaluate clinical efficacy safety 12 mg sublingual tizanidine administer nightly MS patient successfully complete Phase I/II protocol C2/5/TZ : MS-05 Tel Aviv Sourasky Medical Center , Department Neurology , Dr. Arnon Karni , PI .</brief_summary>
	<brief_title>One Year Extension Study To Protocol C2/5/TZ : MS-05</brief_title>
	<detailed_description>The previous study , Protocol C2/5/TZ-MS-05 , use 12 mg sublingual tizanidine , confirm administration nightly sublingual tizanidine sleep result statistically clinically significant reduction next-day spasticity , compare placebo . The clinical effect follow 12 mg sublingual tizanidine large ( 4-5 unit Ashworth scale ) sustain ( 18-20 hour post-dose ) see 8 mg tizanidine ( earlier study , Protocol C2/5/TZ : MS-03z ) . This study also reconfirm increased improvement next-day reduction spasticity follow overnight sublingual tizanidine dose accompany concomitant increase next-day somnolence . This study , 12 month open label extension , allow patient successfully complete Protocol C2/5/TZ-MS-05 find tizanidine beneficial , continue treatment close medical supervision . The study provide long-term ( 12 month ) clinical efficacy safety data : use daily sublingual tizanidine , administer night , bedtime .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Successful completion previous protocol , Study C2/5/TZ : MS05 Have definitive diagnosis Multiple Sclerosis Patients may allow take antispasticity medication study ( Baclofen pump ) per individual daily dose regimen , follow qualification : ( 1 ) No dose 18:00 study day ( 2 ) No dose clinic evaluation day Females must agree use medically accept form birth control , surgically sterile , two year postmenopausal . Oral contraception NOT acceptable contraindicate tizanidine use . Patients must meet criterion stable 24 hour BP value base screen ABPM monitoring ( without tizanidine challenge ) determine study 's BP consultant Use CYP1A2 inhibitor [ e.g . ciprofloxacin fluvoxamine well zileuton , fluroquinolones ( norfloxacin ) , antiarrythmics ( amiodarone , mexiletine , propafenone ) , cimetidine , famotidine , oral contraceptive , acyclovir , ticlopidine ] baseline duration study Taking medication baseline duration study would potentially interfere action study medication outcome variable determine PI Previous history dementia , unstable psychiatric disease current sign symptom significant medical disorder severe , progressive uncontrolled renal , hepatic hematological , endocrine , pulmonary , cardiac , neurological cerebral disease Significant abnormalities screen laboratory parameter describe : ALT &gt; 2xULN AST &gt; 2xULN Creatinine &gt; 2.0 mg/dL Bilirubin &gt; 2xULN WBC &lt; 2,300/mm3 Platelets &lt; 80,000/mm3 History allergy tizanidine inactive component ( include lactose intolerance ) sublingual tizanidine tablet History substance abuse within past 12 month Patients noncooperative unwilling sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Fatigue</keyword>
	<keyword>Spasticity</keyword>
	<keyword>Sublingual Tizanidine</keyword>
	<keyword>Epworth Sleepiness Scale</keyword>
	<keyword>Fatigue Severity Scale</keyword>
</DOC>